The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

FiercePharmaAsia?Biogen-Eisai Alzheimer?s win, Otsuka deals, Samsung BioLogics criminal probe.....           High-stakes talc trial ends in whopping $4.7B verdict for Johnson & Johnson.....           MS patent win boosts Novartis? Gilenya, helps Celgene and maybe Biogen too.....           As U.S. trade war escalates, China rolls out red carpet for Indian drugmakers.....           Adempas maker Bayer connects hypertension patients with new mentoring group.....           Senators challenge Novartis' account of Cohen deal, calling it 'longer and more detailed' than disclosed.....           Genmab, Immatics to develop next-generation bispecific cancer immunotherapies.....           Dermavant to buy rights to tapinarof from GSK for £250m.....           Genentech seeks FDA approval for Venclexta for AML.....           Samsung BioLogics to face criminal probe over accounting fraud for biosims JV.....           Johnson & Johnson enlists diabetes veteran Merck KGaA to hawk Invokana in China.....           Sen. Wyden probes 'secret, sweetheart' deal between Pfizer, Trump.....           Can Mylan dodge Pfizer's Remicade woes with a low-priced Neulasta copy?.....           Otsuka Pharmaceutical to buy biotechnology firm Visterra for $430m.....           AbbVie?s blood cancer drug Ibrutinib fails in phase 3 DLBCL trial.....           FDA grants priority review to Merck?s sBLA for Keytruda to treat advanced hepatocellular carcinoma.....           Lilly Oncology?s strategy? Listen to tough talk from patients?and save data for later.....           Tough time targeting women, pharma? Think time-crunched and family-first: study.....           Pfizer?s bow to Trump won?t just hit its own prices?it?ll put a chill on hikes, period.....           Bristol-Myers Squibb's Opdivo-Yervoy combo wins right to challenge Merck's Keytruda in rare cancer.....           Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's.....           Pharmas call off price hikes after California law forces new warnings: report.....           AbbVie, J&J's Imbruvica comes up short in non-Hodgkin lymphoma trial.....           BioCryst terminates merger deal with Idera Pharmaceuticals.....           Celgene?s anti-PD-L1 immunotherapy plus Abraxane improves PFS in breast cancer study.....           US FTC approves Takeda?s $62bn acquisition of Shire.....           BioNTech, Genevant to co-develop mRNA drugs for rare diseases.....           Accusing OrbiMed as co-conspirator in failed coup, Sinovac aborts go-private deal.....           Gilead?s Kite taps Eisai cancer vet Amoroso to lead the charge for CAR-T sales.....           CMS quietly cancels plan for indication-based pricing on Novartis' Kymriah.....           With Bristol-Myers weighing an OTC sale, could Procter & Gamble bite for more pharma assets?.....           Rubius Therapeutics to invest $155M, hire 160 workers for cell therapy plant.....           Amryt secures funding approval from NHS England for bad cholesterol treatment.....           Hikma secures right to distribute Perrigo's products in MENA markets.....           Teneobio, Janssen to develop multispecific antibodies for oncology.....           EMA recalls heart medicine valsartan made by Chinese firm over potential cancer-causing residue.....           After a Cannes coup, Area 23 creative chief spills his secrets?or most of them.....           Mylan decimates the list price of its Copaxone copy. But why?.....           EMA recalls certain heart drugs containing valsartan over safety fears.....           Sweating it out? Dermira?s armpit awareness push gets Qbrexza ready to roll.....           Trump blasts Pfizer price hikes, pledges a governmental response.....           Sweating it out? Dermira?s armpit awareness push gets Qbrexa ready to roll.....           China speeds cancer drug price cuts amid outcry over smuggled Indian generics.....           Vertex chief, thwarted by NICE, pressures England?s PM to play ball on drug prices.....           Mylan decimates the list price of its Copaxone copy. But why?.....           EMA recalls heart medicine valsartan made by Chinese firm over potential cancer-causing residue.....           Trump blasts Pfizer price hikes, pledges a governmental response.....           Axovant, Benitec sign licensing deal for AXO-AAV-OPMD program.....           Orion begins phase 3 trial of ALS drug levosimendan.....           Herantis Pharma initiates non-invasive CDNF development program.....           Alliance Pharma secures UK approval for nausea drug Diclectin.....           Pharma's digital ad spending is growing?but slowly, research says.....           FiercePharmaAsia?Sanofi?s Chengdu R&D hub, Takeda?s Osaka HQ sale, I-Mab?s $220M financing.....           Judge strikes $140M AndroGel verdict after AbbVie appeal.....           Boehringer Ingelheim BioXcellence adds fill-finish line to China plant.....           Pharma shells out $100B on M&A in 2018 so far, with more to come: report.....           Teva, lured by $40M tax break, packs its bags for New Jersey HQ move.....           EMA accepts Clovis? application for expanded indication of Rubraca to treat ovarian cancer.....           Zynerba halts development of THC prodrug ZYN001.....           EC approves expanded indication for BMS? Sprycel.....           Cellect, denovoMATRIX to combine stem cell production technologies.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Latest news

Call for Nominations for the Eminent Fellowship and Fellowship of the Academy of Pharmaceutical Sciences (APS)

The APS is proud to announce a call for this yearís Nominations for two awards, the

  • Eminent Fellowship (Nominated by an APS member)

  • Fellowship of the Academy (Self-Nominated by an APS member)

These awards recognise and reward science from all sectors where Pharmaceutical Scientists work. The eminent fellowship will be presented at a social networking event held on Thursday 6th September followed by this yearís premier UK Pharmaceutical Sciences Conference, APS@FIP conference in 2018 which will take place in Glasgow on the 7th September 2018.

For more information, click here

Professional recognition for Pharmaceutical Science Degrees

The Academy of Pharmaceutical Sciences (APS) is delighted to announce that the pharmaceutical science course at the University of Greenwich has become the first APS accredited course having successfully completed the accreditation process set up by the Academy towards the end of 2017.

This is the first time that a pharmaceutical science course has been accredited in the United Kingdom and it is also, we believe, a world first.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base here in the UK.

The Academy will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

APS events overview

The APS has developed an exciting and informative programme for our events in 2018.

Donít forget to make a note of APS@FIP, linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference.

Please take a look at our programme, with event summaries, below:

Nanomedicines for the Delivery of Biologics
18 July 2018 - University of Reading
Under the auspices of APS, with special insight from the Nanomedicine focus group, we are proud to announce this new one-day special symposium. This one-day symposium builds on the Recent Emerging Technologies in Therapeutic Oligonucleotides conference in Cambridge, March 2018. We are bringing together world-class speakers with expertise in nanomedicines for the delivery of biologics spanning from bench to bedside. We have assembled an outstanding speaker line-up which includes, but is not limited to, Prof Awyn Jones (University of Cardiff), Prof Yvonne Perrie (University of Strathclyde) and Prof Len Seymour (University of Oxford).
To learn more and to register, click here

7 September 2018 - Hilton Hotel, Glasgow
Linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference, which will take place in the city from the 2 - 6 September 2018. The theme of this conference in 2018 is 'The Science of Differentiated Medicines'.
To learn more and to register, click here

OrBiTo (Innovative Tools for Oral Biopharmaceutics) Conference
Developability for Biologicals
Inhaled Workshop
Basic Biopharmaceutics workshop 

Follow us
Upcoming Events
APS Nanomedicines for the Delivery of Biologics
18 July 2018
7 September 2018
"5 Years of progress in Oral Biopharmaceutics - IMI OrBiTo project and global biopharmaceutics research"
17 - 18 September 2018
APS Industrial Insights 2019
25 - 26 April 2019
10th APS International PharmSci conference 2019
11 - 13 September 2019
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351, Fax: 0116 274 7365, Email:

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.

Privacy Policy:
For details on the data we collect and how we store and process your data please refer to our Privacy Policy.